Connor, Clark & Lunn Investment Management »

Kalaris Therapeutics shares owned by Connor, Clark & Lunn Investment Management

Quarter-by-quarter ownership of Kalaris Therapeutics (KLRS) shares owned by Connor, Clark & Lunn Investment Management from 13F filings

Historical chart of Connor, Clark & Lunn Investment Management investment in Kalaris Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kalaris Therapeutics held by Connor, Clark & Lunn Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kalaris Therapeutics by Connor, Clark & Lunn Investment Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $86k 10k 8.44

More positions owned by Connor, Clark & Lunn Investment Management

Rbc Cad (RY)
Agnico (AEM)
Shopify Cl A Sub Vtg Shs (SHOP)
Toronto Dominion Bk Ont Com New (TD)
Cibc Cad (CM)
NVIDIA Corporation (NVDA)
Bk Nova Cad (BNS)
Apple (AAPL)
Invesco Exch Traded Fd Tr Ii Purbta Msci Us (PBUS)
Microsoft Corporation (MSFT)
Tc Energy Corp (TRP)
Celestica (CLS)
Enbridge (ENB)
Amazon (AMZN)
Barrick Mng Corp Com Shs (B)

View all positions for Connor, Clark & Lunn Investment Management

Top funds holding Kalaris Therapeutics

Samsara BioCapital
Rtw Investments
Paradigm Biocapital Advisors
Siren
Alyeska Investment Group
Ikarian Capital
Vanguard Group
Woodline Partners
ADAR1 Capital Management
Boothbay Fund Management
Raymond James Financial
Renaissance Technologies
Redmile Group
Geode Capital Management
683 Capital Management

View all funds holding Kalaris Therapeutics